AYTU BIOPHARMA, INC Proceeds from Lines of Credit
AYTU BIOPHARMA, INC (AYTU) reported Proceeds from Lines of Credit of $34.79 million for the 3-month period ending 2022-09-30, per its 10-Q/A filed 2023-02-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2023-02-21
- AYTU BIOPHARMA, INC proceeds from lines of credit for the quarter ending 2022-09-30 was $34.79M, a 17.58% decline year-over-year.
- AYTU BIOPHARMA, INC proceeds from lines of credit for the quarter ending 2022-06-30 was $39.77M.
- AYTU BIOPHARMA, INC proceeds from lines of credit for the quarter ending 2021-09-30 was $42.21M.
- AYTU BIOPHARMA, INC proceeds from lines of credit for fiscal 2022 was $152.24M, a 197.30% increase from fiscal 2021.
- AYTU BIOPHARMA, INC proceeds from lines of credit for fiscal 2021 was $51.21M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2022-09-30 | $34.79M 10-Q/A · filed 2023-02-21 | $74.56M derived: sum of 2 quarters · filed 2023-02-21 | ||
| 2022-06-30 | $39.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $152.24M 10-K · filed 2022-09-27 | ||
| 2022-03-31 | $112.46M 10-Q · filed 2022-05-16 | |||
| 2021-09-30 | $42.21M 10-Q/A · filed 2023-02-21 | |||
| 2021-06-30 | $51.21M 10-K · filed 2022-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |